The treatment landscape for atopic dermatitis has undergone a transformation in the last seven years, spurred largely by the launch of Sanofi and Regeneron’s blockbuster IL-4/IL-13 inhibitor Dupixent (dupilumab) in 2017. Today, there are a range of topical, oral and biologic drugs and different mechanisms of action available to treat moderate-to-severe atopic dermatitis, but many patients continue to experience persistent itching and remain uncontrolled.
Atopic Dermatitis Market Snapshot: A Crowded Field With Room To Grow
Topical, oral and biologic drugs have made a difference for patients with atopic dermatitis, but full control remains elusive for many, with the heterogeneous condition, leaving open a door for new medications.
